• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与米托坦反应中间体结合的肾上腺蛋白。

Adrenal proteins bound by a reactive intermediate of mitotane.

作者信息

Cai W, Counsell R E, Schteingart D E, Sinsheimer J E, Vaz A D, Wotring L L

机构信息

College of Pharmacy, University of Michigan, Ann Arbor 48109-1065, USA.

出版信息

Cancer Chemother Pharmacol. 1997;39(6):537-40. doi: 10.1007/s002800050610.

DOI:10.1007/s002800050610
PMID:9118466
Abstract

PURPOSE

Mitotane (o,p'-DDD), is the only adrenolytic agent available for the treatment of adrenocortical carcinoma. Previous studies have shown that mitotane covalently binds to adrenal proteins following its metabolism in adrenocortical tissue to a reactive acyl chloride intermediate. It was the objective of this study to compare the electrophoresis separation patterns of such adducts following activation of mitotane by various adrenocortical sources.

METHODS

With the use of a 125I-labeled analog of mitotane, 1-(2-chlorophenyl)-1-(4-iodophenyl)-2,2-dichloroethane, gel electrophoresis patterns were obtained for homogenates from bovine, canine and human adrenocortical preparations as well as from a human adrenal preparation. Western immunoblotting analysis was used to test the resulting patterns for adducts of cytochrome P-450scc and adrenodoxin.

RESULTS

The electrophoresis separations were similar for all preparations, with bands at apparent molecular weights of 49.5 and 11.5 kDa being the most pronounced. Radiolabeling of the proteins of a human adrenal cancer cell line NCI H-295 was weak, but a band at 11.5 kDa was detected. Western immunoblotting analyses indicated that the band at 49.5 kDa corresponded in molecular weight to that of adrenal cytochrome P-450scc, but the band at 11.5 kDa did not correspond to adrenodoxin.

CONCLUSIONS

The similarity of the results with canine and bovine adrenal preparations to that of human material offers useful systems for studying mitotane and its analogs. This should aid in understanding the mechanism of action of mitotane and in the design of compounds for the treatment of adrenocortical carcinoma.

摘要

目的

米托坦(邻,对'-滴滴滴)是唯一可用于治疗肾上腺皮质癌的肾上腺溶解剂。先前的研究表明,米托坦在肾上腺皮质组织中代谢为反应性酰氯中间体后,会与肾上腺蛋白共价结合。本研究的目的是比较米托坦经各种肾上腺皮质来源激活后此类加合物的电泳分离模式。

方法

使用米托坦的125I标记类似物1-(2-氯苯基)-1-(4-碘苯基)-2,2-二氯乙烷,获得了来自牛、犬和人肾上腺皮质制剂以及人肾上腺制剂匀浆的凝胶电泳图谱。采用蛋白质免疫印迹分析来检测细胞色素P-450scc和肾上腺铁氧化还原蛋白加合物的所得图谱。

结果

所有制剂的电泳分离结果相似,最明显的条带出现在表观分子量为49.5 kDa和11.5 kDa处。人肾上腺癌细胞系NCI H-295蛋白质的放射性标记较弱,但检测到一条11.5 kDa的条带。蛋白质免疫印迹分析表明,49.5 kDa处的条带分子量与肾上腺细胞色素P-450scc相对应,但11.5 kDa处的条带与肾上腺铁氧化还原蛋白不对应。

结论

犬和牛肾上腺制剂的结果与人材料的结果相似,为研究米托坦及其类似物提供了有用的系统。这应有助于理解米托坦的作用机制以及设计用于治疗肾上腺皮质癌的化合物。

相似文献

1
Adrenal proteins bound by a reactive intermediate of mitotane.与米托坦反应中间体结合的肾上腺蛋白。
Cancer Chemother Pharmacol. 1997;39(6):537-40. doi: 10.1007/s002800050610.
2
Metabolic activation and binding of mitotane in adrenal cortex homogenates.
J Pharm Sci. 1995 Feb;84(2):134-8. doi: 10.1002/jps.2600840203.
3
Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers.米托坦[1-(2-氯苯基)-1-(4-氯苯基)-2,2-二氯乙烷;邻,对'-滴滴滴]及其对,对'-和间,对'-异构体的牛肾上腺皮质转化
Biochem Pharmacol. 1995 May 17;49(10):1483-9. doi: 10.1016/0006-2952(95)00028-x.
4
Comparative CYP-dependent binding of the adrenocortical toxicants 3-methylsulfonyl-DDE and o,p'-DDD in Y-1 adrenal cells.肾上腺皮质毒物3-甲基磺酰基-DDE和邻,对'-滴滴滴在Y-1肾上腺细胞中细胞色素P450依赖性结合的比较
Arch Toxicol. 2007 Nov;81(11):793-801. doi: 10.1007/s00204-007-0206-5. Epub 2007 May 9.
5
Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.米托坦与乳糜微粒和血清脂蛋白的关联:对治疗肾上腺皮质癌的实际意义。
Eur J Endocrinol. 2016 Mar;174(3):343-53. doi: 10.1530/EJE-15-0946. Epub 2015 Dec 15.
6
Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p'-DDD in human adrenal zona fasciculata/reticularis.细胞色素P450催化3-甲基磺酰基-DDE和邻,对'-滴滴滴在人肾上腺束状带/网状带中的结合。
J Clin Endocrinol Metab. 2002 Mar;87(3):1319-26. doi: 10.1210/jcem.87.3.8281.
7
Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane.米托坦诱导的H295R肾上腺皮质细胞系蛋白质组学图谱的调节
Endocr Relat Cancer. 2008 Mar;15(1):1-10. doi: 10.1677/ERC-07-0003.
8
Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.米托坦增强了放疗抑制作用,并在联合治疗中诱导H295R和SW13肾上腺皮质细胞系出现G2期阻滞。
Endocr Relat Cancer. 2008 Jun;15(2):623-34. doi: 10.1677/erc.1.1315.
9
Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p,'-DDD). Correlation between adrenocorticolytic activity and metabolic activation by adrenocortical mitochondria.1-(邻氯苯基)-1-(对氯苯基)-2,2-二氯乙烷(邻,对'-滴滴滴)的代谢与共价结合。肾上腺皮质线粒体的肾上腺皮质溶解活性与代谢活化之间的相关性。
Drug Metab Dispos. 1980 May-Jun;8(3):127-30.
10
The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p'-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect.
Drug Metab Dispos. 1977 Sep-Oct;5(5):482-6.

引用本文的文献

1
Therapeutic frontiers in adrenocortical carcinoma: from standards to innovation.肾上腺皮质癌的治疗前沿:从标准到创新。
Med Oncol. 2025 Jul 3;42(8):311. doi: 10.1007/s12032-025-02864-5.
2
A review of mitotane in the management of adrenocortical cancer.关于米托坦治疗肾上腺皮质癌的综述。
Oncologist. 2024 Sep 6;29(9):747-760. doi: 10.1093/oncolo/oyae084.
3
Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies.肾上腺皮质癌的生物学和基因组学最新进展:新兴治疗策略的理论基础。
Endocr Rev. 2022 Nov 25;43(6):1051-1073. doi: 10.1210/endrev/bnac012.
4
Editorial Comment to Local advanced adrenocortical cancer with a long-term recurrence-free survival treated with complete surgical excision and adjuvant therapy with a very low-dose mitotane.关于采用完整手术切除及极低剂量米托坦辅助治疗实现长期无复发生存的局部晚期肾上腺皮质癌的编辑评论
IJU Case Rep. 2020 Aug 29;3(6):236. doi: 10.1002/iju5.12215. eCollection 2020 Nov.
5
CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.CYP11B1 在人肾上腺皮质癌细胞中不参与米托坦的作用及其代谢。
PLoS One. 2018 May 7;13(5):e0196931. doi: 10.1371/journal.pone.0196931. eCollection 2018.
6
CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma.细胞色素P450 2W1(CYP2W1)在肾上腺中高表达,且与肾上腺皮质癌对米托坦的反应呈正相关。
PLoS One. 2014 Aug 21;9(8):e105855. doi: 10.1371/journal.pone.0105855. eCollection 2014.
7
The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.邻,对二氯二苯二氯乙烷(o,p'DDA)缺乏抗肿瘤作用,排除了其作为米托坦的活性代谢产物用于肾上腺皮质癌治疗的作用。
Horm Cancer. 2014 Oct;5(5):312-23. doi: 10.1007/s12672-014-0189-7. Epub 2014 Jul 16.
8
Adrenocortical carcinoma.肾上腺皮质癌。
Endocr Rev. 2014 Apr;35(2):282-326. doi: 10.1210/er.2013-1029. Epub 2013 Dec 20.